Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07137494 · ClinicalTrials.gov registry record · Phase 1

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

A Phase 1 study of Secondary Central Nervous System Lymphoma and Primary Central Nervous System (CNS) Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
7
Study locations

NCT07137494 is a Phase 1 study of Secondary Central Nervous System Lymphoma and Primary Central Nervous System (CNS) Lymphoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants, below the 38-participant average among 7 other Secondary Central Nervous System Lymphoma trials with a reported enrollment target (68% lower). The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07137494, a Phase 1 study of Secondary Central Nervous System Lymphoma and Primary Central Nervous System (CNS) Lymphoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
7
Study locations

Study Summary

This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.

Conditions Studied

Secondary Central Nervous System Lymphoma Primary Central Nervous System (CNS) Lymphoma

Interventions

  • BIOLOGICAL MB-CART19.1 Cellular Therapy

Study Locations (7)

New York

  • Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering at Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering at Nassau (Limited Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2025-08-14
Est. Completion 2028-08
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07137494

The ClinicalTrials.gov registry entry for NCT07137494 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38-participant average among 7 other Secondary Central Nervous System Lymphoma trials with a reported enrollment target (68% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Secondary Central Nervous System Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which MB-CART19.1 Cellular Therapy is the first listed.

NCT07137494 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT07137494 about?

NCT07137494 is a clinical study titled "A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)". This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.

What is the current status of trial NCT07137494?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-08-14. Estimated completion is 2028-08.

What conditions does trial NCT07137494 study?

This clinical trial studies the following conditions: Secondary Central Nervous System Lymphoma, Primary Central Nervous System (CNS) Lymphoma.

What interventions are being tested in trial NCT07137494?

The interventions under investigation include: MB-CART19.1 Cellular Therapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT07137494?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07137494 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Secondary Central Nervous System Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Secondary Central Nervous System Lymphoma

All registered trials for this condition

Primary Central Nervous System (CNS) Lymphoma

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.